HEALTH CATALYST ($HCAT) posted quarterly earnings results on Wednesday, May 7th. The company reported earnings of $0.01 per share, beating estimates of $0.00 by $0.01. The company also reported revenue of $79,410,000, missing estimates of $80,752,298 by $-1,342,298.
You can see Quiver Quantitative's $HCAT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HEALTH CATALYST Insider Trading Activity
HEALTH CATALYST insiders have traded $HCAT stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $HCAT stock by insiders over the last 6 months:
- DANIEL LESUEUR (Chief Operating Officer) has made 0 purchases and 5 sales selling 55,302 shares for an estimated $342,319.
- BENJAMIN LANDRY (General Counsel) has made 0 purchases and 3 sales selling 35,595 shares for an estimated $241,950.
- JASON ALGER (Chief Financial Officer) sold 19,599 shares for an estimated $163,049
- LINDA LLEWELYN (Chief People Officer) has made 0 purchases and 4 sales selling 20,690 shares for an estimated $134,697.
- KEVIN LEE FREEMAN (Chief Commercial Officer) sold 7,500 shares for an estimated $67,073
- DUNCAN GALLAGHER has made 0 purchases and 2 sales selling 9,000 shares for an estimated $62,599.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HEALTH CATALYST Hedge Fund Activity
We have seen 80 institutional investors add shares of HEALTH CATALYST stock to their portfolio, and 74 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NEPSIS INC. added 1,994,555 shares (+2072.1%) to their portfolio in Q1 2025, for an estimated $9,035,334
- BANK OF NEW YORK MELLON CORP removed 1,238,206 shares (-86.2%) from their portfolio in Q1 2025, for an estimated $5,609,073
- FIRST LIGHT ASSET MANAGEMENT, LLC added 944,631 shares (+22.0%) to their portfolio in Q4 2024, for an estimated $6,678,541
- ALYESKA INVESTMENT GROUP, L.P. added 861,150 shares (+74.4%) to their portfolio in Q4 2024, for an estimated $6,088,330
- KENNEDY CAPITAL MANAGEMENT LLC added 565,445 shares (+42.7%) to their portfolio in Q4 2024, for an estimated $3,997,696
- GRANAHAN INVESTMENT MANAGEMENT, LLC removed 539,119 shares (-52.2%) from their portfolio in Q4 2024, for an estimated $3,811,571
- PENN CAPITAL MANAGEMENT COMPANY, LLC added 495,945 shares (+inf%) to their portfolio in Q4 2024, for an estimated $3,506,331
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HEALTH CATALYST Analyst Ratings
Wall Street analysts have issued reports on $HCAT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- KeyBanc issued a "Overweight" rating on 04/16/2025
To track analyst ratings and price targets for HEALTH CATALYST, check out Quiver Quantitative's $HCAT forecast page.
HEALTH CATALYST Price Targets
Multiple analysts have issued price targets for $HCAT recently. We have seen 3 analysts offer price targets for $HCAT in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Scott Schoenhaus from KeyBanc set a target price of $5.0 on 04/16/2025
- An analyst from Stephens set a target price of $5.0 on 03/06/2025
- Sean Dodge from RBC Capital set a target price of $7.0 on 01/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
